Roche Holding AG (OTCMKTS:RHHBY) Shares Sold by Saratoga Research & Investment Management

Saratoga Research & Investment Management reduced its position in Roche Holding AG (OTCMKTS:RHHBY) by 6.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,174,306 shares of the company’s stock after selling 151,504 shares during the period. Roche comprises about 3.8% of Saratoga Research & Investment Management’s holdings, making the stock its 10th largest position. Saratoga Research & Investment Management’s holdings in Roche were worth $75,840,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in RHHBY. SVB Wealth LLC bought a new stake in Roche in the fourth quarter worth $555,000. Altrius Capital Management Inc lifted its position in shares of Roche by 0.3% in the fourth quarter. Altrius Capital Management Inc now owns 183,448 shares of the company’s stock worth $6,399,000 after buying an additional 603 shares during the last quarter. Verity Asset Management Inc. boosted its stake in shares of Roche by 26.8% during the 4th quarter. Verity Asset Management Inc. now owns 8,036 shares of the company’s stock worth $280,000 after acquiring an additional 1,697 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in shares of Roche by 0.9% during the 4th quarter. Hantz Financial Services Inc. now owns 33,708 shares of the company’s stock valued at $1,176,000 after acquiring an additional 305 shares during the last quarter. Finally, Brooklyn Investment Group raised its stake in shares of Roche by 36.6% in the 4th quarter. Brooklyn Investment Group now owns 1,354 shares of the company’s stock valued at $48,000 after acquiring an additional 363 shares in the last quarter.

Roche Price Performance

Shares of OTCMKTS RHHBY opened at $41.92 on Monday. Roche Holding AG has a 12 month low of $29.20 and a 12 month high of $44.31. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86. The business’s 50 day moving average is $41.17 and its two-hundred day moving average is $38.69.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. UBS Group raised Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Morgan Stanley initiated coverage on shares of Roche in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, Sanford C. Bernstein raised shares of Roche to a “strong-buy” rating in a research report on Thursday, January 30th. Two analysts have rated the stock with a sell rating, one has given a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Roche has a consensus rating of “Moderate Buy”.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.